The programme touches upon price-sensitive announcements during early trading hours in the Australian market that would impact stock movement. Watch The Stocks in Action on Kalkine TV and stay updated.
• Medlab Clinical (ASX:MDC), an Australian biotech using delivery platforms to enhance medicine has shared that it has got human ethics approval for Australian sites for the NanaBis™ Cancer bone pain Phase III trial.
• Belberry Limited, a well-known Australian Human Research Ethics Committee (HREC), has granted approvals for Principal Investigators Prof Stephen Clarke at GenesisCare, Sydney and Prof Phil Good at the Mater Hospital, Brisbane.
• Well, NanaBis™ is Medlab’s most advanced non-opioid pain medication utilising Medlab’s patented, delivery platform, NanoCelle®.
• Shares of NRW were trading high, post the company updated it would sell its major mining equipment to Boggabri Coal Operations.
• Boggabri Coal is a part of Idemitsu Group and can exercise options to acquire a majority of mining equipment of Golding Contractors, a wholly-owned subsidiary of NWH, engaged in the Maintenance of the Boggabri Coal Mine.
• TheraJoint+, a highly potent turmeric supplement, was created after conducting a deep dive survey. The responses revealed significant consumer demand for a solution to the discomfort of joint pain and general whole-body inflammation.